Join us at the 5th Annual Oligonucleotide & Precision Therapeutics Congress

Based on the resounding success of last year’s inaugural 2 day program dedicated to Oligonucleotide CMC & Regulatory Strategies we will once again be adding this content to complement our established Oligonucleotide Discovery and Delivery conference. In addition, we deliver two in-depth symposiums focusing on Rare Disease Drug Development and NEW for 2020: AI in Drug Discovery and Development. Bringing together leading discovery scientists, developers, CMC experts, regulatory specialists and technology providers, OPT Congress provides a unique opportunity to discuss advances in next-generation oligonucleotide therapies throughout the drug development process. Attend in 2020 to optimize your drug design, delivery and performance, accelerate time to market and achieve commercial success.

65%
of Attendees
from Biotech
15%
of Attendees
from Pharma
130+
Unique
Organizations
10+
Hours of
Networking

With thanks to our Executive Advisory Board

Arthur Levin, PhD
Executive Vice President, Research and Development, Avidity Biosciences

Muthiah (Mano) Manoharan, PhD
Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals

Lubo Nechev, PhD
Vice President Process and Analytical Sciences, Alnylam Pharmaceuticals

Dmitry Samarsky, PhD
CTO, Sirnaomics



Premier Sponsor

Oligo-Factory